載入中
NASDAQHealthcareMedical - Devices
最新資料
US$18.40
+US$0.50 · +2.79%
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
前收盤價
US$18.40
+US$0.50 · +2.79%
盤中時間採用ET。市場資料可能有所延遲。
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
日內區間
目前US$18.40
52週區間
目前US$18.40
盤中時間採用ET。市場資料可能有所延遲。
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
日內區間
目前US$18.40
52週區間
目前US$18.40
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.08億 USD | 2.24億 USD | 1.36億 USD | 7501.4萬 USD | 3447.3萬 USD |
| 銷貨成本 | 1.12億 USD | 8739.9萬 USD | 6514.2萬 USD | 3792.9萬 USD | 1860.8萬 USD |
| 毛利 | 1.96億 USD | 1.37億 USD | 7104.9萬 USD | 3708.5萬 USD | 1586.5萬 USD |
| 研究與開發 | 7127.7萬 USD | 6229.8萬 USD | 4844.6萬 USD | 2898.1萬 USD | 1899.3萬 USD |
| 銷售、一般及管理費用 | 2.29億 USD | 1.71億 USD | 1.32億 USD | 8882.8萬 USD | 5103.6萬 USD |
| 營業費用 | 3億 USD | 2.34億 USD | 1.8億 USD | 1.18億 USD | 7002.9萬 USD |
| 利息收入 | 1221.9萬 USD | 1089.5萬 USD | 755.1萬 USD | 249.7萬 USD | 7.6萬 USD |
| 利息支出 | 358.6萬 USD | 418.4萬 USD | 399.5萬 USD | 518.3萬 USD | 581萬 USD |
| 折舊和攤銷 | 639萬 USD | 523.4萬 USD | 380.7萬 USD | 284.1萬 USD | 332.4萬 USD |
| 營業利益 | −1.04億 USD | −9661.4萬 USD | −1.09億 USD | −8072.4萬 USD | −5416.4萬 USD |
| 淨利 | −9557.2萬 USD | −9141.3萬 USD | −1.06億 USD | −8715.4萬 USD | −5985.3萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
